Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Activity in H1 2016



Libourne – 21 July 2016 – Fermentalg, an industrial biotechnology company that specializes in the production of oils and proteins derived from microalgae, has reported on activity during the first half of 2016.


En route towards the commercialization of DHA
The start to 2016 was marked by 2 major advances in the commercialization of DHA (Omega 3):

the signing of an industrial agreement for the large-scale production of DHA with ARD, a company specializing in bio-refining, industrial biotechnologies and bio-based chemistry;
the completion of the DHA process book which is the last stage in pre-industrialization at the company's scientific facilities in Libourne and opens the way for large-scale production.

With this in mind, Fermentalg has confirmed that it intends to launch this first product on the market between now and the end of the year.


Development milestones for the 4 other portfolio products
Alongside DHA, which is currently its most advanced product, Fermentalg has continued with the scientific and pre-industrial development work needed to launch 4 additional products between now and 2020 (DHA+, BM Bastille, Phycocyanine and Astaxanthin).


IDU construction calendar confirmed
Fermentalg also went ahead with the construction of its Industrial Development Unit (IDU) in Libourne (Gironde). So far, the building which is scheduled for delivery in the third quarter of 2016 has represented an investment of €6.2 million (out of a total estimated budget of €23 million). Commissioning, which is tied to the start of on-site production, is still planned for 2018.


€22.3 million in cash at end-June 2016
Revenues generated through partnerships amounted to €0.17 million in the first half of 2016 (compared with €0.7 million for the same period in 2015).


Thanks to its strict management, Fermentalg has the robust and healthy financial footing needed to execute its strategic roadmap. Gross cash stood at €22.3 million on 30 June 2016.


About Fermentalg
Fermentalg is an industrial biotechnology company that specializes in producing sustainable oils and proteins derived from the exceptional properties of microalgae. Based in Libourne (Gironde), the company is looking to market 5 products between now and 2020: DHA, DHA+, BM Bastille, Phycocyanine and Astaxanthin. Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG). For more information, visit the Fermentalg website at: www.fermentalg.com.
















 
Press Relations:
 
Investor Relations:
   
ACTUS finance & communication
Alexandra Prisa
Tel: +33 (0)1 53 67 36 90
[email protected]
ACTUS finance & communication
Jérôme Fabreguettes-Leib
Tel: +33 (0)1 53 67 36 78
[email protected]

Regulated information
Releases under ongoing disclosure requirements:
- Permanent Information Releases, sales and Revenues
Full and original press release in PDF:

https://www.actusnews.com/documents_communiques/ACTUS-0-45068-2016-07-21-FERMENTALG-CA-S1-2016-vDEF-EN.pdf

Receive by email the next press releases of the company by registering on
www.actusnews.com, it's free



Source: Actusnews

Fermentalg S.A. Stock

€0.51
-0.200%
Fermentalg S.A. shows a slight decrease today, losing -€0.001 (-0.200%) compared to yesterday.

Like: 0
Share

Comments